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Abstract
Study Design: Retrospective cohort study.
Objectives: (1) To assess patient-reported outcomes—physical function, pain, and quality of life—in patients who underwent
resection of a mobile spine chondrosarcoma. (2) To assess complications (90 days), readmissions, reoperations, oncological
outcomes, and neurologic status.
Methods: Thirty-three patients with spinal conventional chondrosarcoma resection between 1984 and 2014 at one hospital
were included. The primary outcome measures were—minimally 6 months after surgery—the EuroQol 5 Dimensions (EQ5D),
PROMIS–Physical Function, PROMIS–Pain Intensity, and Oswestry (ODI) Disability Index, or Neck (NDI) Disability established in
14 out of 20 alive (70.0%) patients. Complications, readmission, reoperations, oncological outcomes, and neurological status were
reported for the complete cohort of 33 patients.
Results: After spine chondrosarcoma resection, patients (n ¼ 14) reported worse physical function (median 43, range 22-61,
P ¼ .026), worse quality of life (median EQ5D 0.70, range 0.04-1, P ¼ .022), and comparable pain intensity (median 47, range
31-56, P ¼ .362) when compared with US general population values. The median NDI/ODI was 25 (range 0-72) indicating mild to
moderate disability. Patients undergoing reoperation had worse patient-reported outcomes than those who did not. Eighteen
(55.5%) out of 33 patients suffered complications (90 days), 14 (42.4%) had unplanned readmission, and 13 (39.4%) underwent
reoperation. Intralesional resection was associated with increased readmission, reoperation, and recurrence rate.
Conclusions: Chondrosarcoma affects quality of life and physical function and its treatment frequently results in complications
and reoperations. Our findings can be used to inform future patients about expected outcomes.
Keywords
chondrosarcoma, spine surgery, patient-reported outcomes, complications, reoperations, readmissions.
Introduction
Chondrosarcomas account for 20% to 27% of malignant bone
tumors,1,2 and 10% arise from the mobile spine.3-6 Spinal chon-
drosarcoma resection with negative margins has been shown to
improve local control and survival2-4,7-10; a complicating factor
is the anatomy that often makes en bloc resection with negative
margins technically difficult. Furthermore, these surgeries are
associated with substantial morbidity.11,12
The key aim of surgical resection is to achieve local tumor
control and improve life expectancy. However, as long-term
survival for these patients have improved due to better surgical
and adjuvant treatment,5,13 functional outcome and quality of
life become important outcomes that the patient needs to be
informed about.14,15 Previous studies on spinal chondrosar-
coma have reported on oncological outcomes; however,
patient-reported outcome has not been studied.3-6,9,16-18
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Primarily, we assessed patient-reported outcomes—physical
function, pain, and quality of life—in patients who underwent
resection of a mobile spine chondrosarcoma and were avail-
able for follow-up. Secondarily, we assessed complications
(90 days), readmissions, reoperations, oncological outcomes,
and neurologic status in the complete cohort. We reported
overall outcomes, and reported outcomes based on type of
resection (en bloc vs intralesional) including margin status
(negative vs positive).
Materials and Methods
Study Design and Participants
Our institutional review board approved this study and a waiver
of consent was granted. We included patients aged 18 years or
older, who underwent primary or secondary resection of a
mobile spine chondrosarcoma at our Orthopaedic Spine Oncol-
ogy Service between 1984 and 2014. Secondary resection
includes resection of a recurrence or residual tumor after
previous surgery at a different institution. Exclusion criteria
were: nonconventional chondrosarcoma (dedifferentiated,
secondary, mesenchymal, juxtacortical, and clear cell) and
chondrosarcoma of a nonspinal origin metastasized to the
spine. Thirty-three patients met these criteria and were
identified by word-based queries searching operative and
pathological reports in our orthopedic oncology database.
In February 2015 we sent an invitation letter to complete an
online survey to 20 patients who were alive and had a minimum
follow-up of 6 months (reminder at 2 and 8 months); 14 out of
20 patients (70.0%) completed all surveys. We were unable to
contact 4 patients, and 2 refused participation. Survey data was
collected using Assessment Center (Northwestern University
Feinberg School of Medicine, Chicago, IL, USA, 2007).19
Patient-reported outcomes were analyzed for those who
completed the survey (n ¼ 14), whereas all other outcomes
(complications, readmissions, reoperations, oncological out-
comes, and neurologic status) are described for the complete
cohort (n ¼ 33).
Treatment
Whenever achievable, we treat spinal chondrosarcomas by en
bloc resection with negative margins, in conjunction with
neoadjuvant or adjuvant photon/proton radiation and—when
the tumor abuts the dura—intraoperative dural plaque radiation
to address any dural tumor seeding.13 The majority are treated
by a 2-stage procedure; the first stage consists of posterior
stabilization (with or without decompression of the spinal
canal), and excision of the tumor is performed by an anterior
approach in the second surgery. Relatively healthy patients
with favorable neurologic and oncologic status, or those with
tumor locations amenable to such, may be treated by a com-
bined (anterior and posterior) approach in a single surgery.
Patients will undergo intralesional resection if the tumor
location, size, or proximity to adjacent viscera or major vessels
hinders resection with negative margins. Residual or recurrent
tumors are often more challenging and are more likely to result
in intralesional resection.4,17,20
Outcomes and Explanatory Variables
Our primary outcome measures were the PROMIS (Patient-
Reported Outcomes Measurement Information System)
Physical Function (Cancer Bank), PROMIS Pain Intensity,
EuroQol 5 Dimensions (EQ5D), and the Oswestry Disability
Index (ODI; thoracolumbar lesions) or Neck Disability Index
(NDI; cervical lesions) reflecting the health status of the patient
at time of survey completion.21-25
The raw score of each PROMIS questionnaire is trans-
formed into a t-score; a standardized score with a mean of
50 (US general population) and a standard deviation of 10. A
higher PROMIS Physical Function t-score corresponds to bet-
ter physical function.22,23,26 A higher PROMIS Pain Intensity
score corresponds to more pain.
The EQ5D questionnaire is a generic short form with 5
items, and assesses quality of life.21,27 Higher scores indicate
better quality of life. We compared scores with the US popu-
lation average of 0.85.28
ODI and NDI scores range from 0 to 100, with higher scores
indicating more disability.24,25,29
No questions regarding any of the secondary outcome mea-
sures were included in the questionnaires sent to patients to
avoid bias.
Secondary outcome measures were complications (90 days),
readmissions, reoperations, local recurrence rate, new metas-
tases after surgery, disease-specific survival (from medical
charts and from the Social Security Death Index),30 and neu-
rologic status at final follow-up. We categorized complications
(90 days) into minor (ie, requiring pharmacological treatment,
except for commonly used postoperative medications [eg,
analgesics] and blood transfusion as all patients had blood
transfusions) and major (ie, requiring surgical, endoscopic, or
radiological intervention).31
Baseline characteristics at time of surgery were age, Body
mass index (BMI) in kg/m2, sex, smoking status, type of lesion,
and symptoms at presentation. Oncologic preoperative vari-
ables were tumor location, World Health Organization (WHO)
pathologic tumor grade,8,32 Enneking tumor staging,33 extent
of the lesion (Weinstein-Boriani-Biagini [WBB] system),34
tumor growth into local neurovascular structures, prior tumor
embolization, and prior radiotherapy or chemotherapy. Surgi-
cal variables were: primary resection or (secondary) resection
of a recurrence/residual tumor, year, approach, intraoperative
radiotherapy, and resection margin status (positive defined as
tumor tissue at the surface of the specimen).
Statistical Analysis
Categorical variables are presented with frequencies and per-
centages, and continuous variables with median, interquartile
range (IQR), and range. We used the Mann-Whitney U test and
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the Fisher exact test to analyze differences between patients
treated by en bloc resection with negative margins versus intra-
lesional or en bloc resection with positive margins. We used the
one sample signed rank test to assess whether scores differed
from US population averages. We calculated differences in
patient-reported outcomes for explanatory variables using the
Mann-Whitney U test. We used the log-rank test to analyze
differences for specific explanatory variables for oncologic
outcomes. We performed all analyses with Stata 13.0 (Stata-
Corp LP, College Station, TX, USA) and considered 2-tailed
P values less than .05 as significant.
Results
Baseline Characteristics
The median age was 48 years (range 24-66 years), 20 (60.6%,
20/33) were men and the median BMI was 25 kg/m2 (IQR 24-
29 kg/m2) (Table 1). Most patients presented with back pain
(71.9%, 23/32), 35.5% (11/31) had neurologic deficits, and
most tumors were located in the thoracic spine (72.7%,
24/33). Twenty-eight (85%, 28/33) were WHO grade I-II
tumors, 3 (9.1%, 3/33) patients had a preoperative metastasis
(2 locoregionally in the spine, 1 in the lung) (Table 2). Eighteen
(54.5%, 18/33) patients had received local radiotherapy,
4 (12.5%, 4/32) underwent preoperative embolization, and
3 (9.1%, 3/33) had preoperative chemotherapy—all 3 with
Adriamycin. Nineteen (57.6%, 19/33) patients underwent their
first resection elsewhere (Figure 1).
We performed 18 (54.5%, 18/33) en bloc resections, and
obtained negative resectionmargins in 13 (72.2%, 13/18) of these
cases (Table 3); 8 wide resection margins (ie, continuous shell of
healthy tissue around the tumor), and 5 marginal resection mar-
gins (ie, tumormass coveredmostly byonly a “pseudocapsule”).4
Twenty patients (60.6%, 20/33) had a combined—that is,
posterior and anterior—approach, of which 15 patients (75%,
15/20) in a 2-staged fashion. Nine patients (27.3%) received
intraoperative radiotherapy; 7 by intraoperative dural plaque bra-
chytherapy, 2 by external beam therapy (20 kV peak applicator).
Patients who underwent en bloc resection with negative
margins more often were neurologically intact as compared
with patients who underwent intralesional resection or en bloc
resection with positive margins (P ¼ .024) (Table 1). There
were no other differences in baseline, oncological, or surgical
characteristics between these 2 groups (Tables 1-3).
Eighteen (54.5%, 18/33) patients had a single-stage proce-
dure lasting for a median of 9 hours (IQR 7-12 hours, available
in 11 patients) with a median blood loss of 1 L (IQR 1-2 L,
available in 13 patients) (Table 4). Fifteen (45.5%, 15/33)
patients had a 2-stage procedure; first-stage surgeries lasted for
a median of 7 hours (IQR 5-9 hours, available in 12 patients)
with a median blood loss of 2 L (IQR 1-2 L, available in
13 patients); second-stage surgeries lasted for a median of 8
Table 1. Baseline Characteristics for Patients With Primary Chondrosarcoma in the Mobile Spine Treated by En Bloc ResectionWith Negative
Margins or En Bloc Resection With Positive Margins/Intralesional Surgery.
All Patients, n ¼ 33
En Bloc Negative
Margins, n ¼ 13
Intralesional/En Bloc
Positive Margins, n ¼ 20
Baseline Characteristics Median (IQR) Median (IQR) Median (IQR) Pa
Age (years) 48 (39-58) 54 (47-58) 44 (37-58) .223
Body mass index (kg/m2)b 25 (24-29) 26 (24-30) 25 (24-27) .696
n (%) n (%) n (%)
Male sex 20 (60.6) 9 (69.2) 11 (55.0) .485
Smoking statusb
Never smoker 20 (71.4) 8 (66.7) 12 (75.0) .496
Quit for at least 1 year 4 (14.3) 3 (25.0) 1 (6.3)
Current smoker 4 (14.3) 1 (8.3) 3 (18.8)
Back painb 23 (71.9) 9 (69.2) 14 (73.7) .999
Palpable massb 5 (15.6) 2 (15.4) 3 (15.8) .999
Neurologic impairmentb
Yes (ASIA score A-D) 11 (35.5) 1 (8.3) 10 (52.6) .024
No (ASIA score E) 20 (64.5) 11 (91.7) 9 (47.4)
Compression fractureb 4 (12.9) 0 (0) 4 (21.1) .318
Lesion typeb
Osteolytic 13 (68.4) 4 (66.7) 9 (69.2) .927
Osteoblastic 1 (5.3) 0 (0) 1 (7.7)
Mixed osteolytic and osteoblastic 5 (26.3) 2 (33.3) 3 (23.1)
Abbreviation: ASIA, American Spinal Injury Association.
a P values are based on differences between the patients treated by en bloc resection with negative margins versus intralesional resection or en bloc resection with
positive margins. Boldfaced P value indicates significance (P < .05).
bData for body mass index was available in 21 patients (64%), smoking status in 28 patients (85%), back pain in 32 patients (97%), palpable mass in 32 patients (97%),
neurologic impairment in 31 patients (94%), compression fracture in 31 patients (94%), and lesion type in 19 patients (58%)
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hours (IQR 6-8 hours, available in 10 patients) with a median of
2 L of blood loss (IQR 1-3 L, available in 8 patients). The
median stay at the surgical intensive care unit was 1 day (IQR
1-6 days, range 0-38 days).
The median clinical follow-up for all 33 patients was
24 months (IQR 9-96 months). Clinical follow-up was less than
6 months for 3 (9.1%) cases (7, 36, and 113 days). The median
follow-up for the 14 patients answering questionnaires was
5 years (IQR 13-129 months, range 6 months to 18 years).
Patient-Reported Outcomes (n ¼ 14)
Compared with the US general population values, patients with
spinal chondrosarcoma had worse physical function (median
t-score 43, range 22-61, P ¼ .026), and worse quality of life
(median EQ5D 0.70, range 0.04-1, P¼ .022). Pain intensity was
comparable to theUSpopulationvalues (median t-score47, range
31-56, P ¼ .362). The median NDI/ODI was 25 (range 0-72)
indicating mild to moderate disability (Tables 5 and 6).24,25,29
Patients who underwent reoperation after surgery at our
institution (5/14) had worse physical function (P ¼ .004),
worse quality of life (P ¼ .004), and were more severely dis-
abled (P ¼ .003) when compared with patients who did no
undergo reoperation (9/14) (Table 5).
Complications (90 Days), Readmissions,
and Reoperations (n ¼ 33)
Thirty-two complications (90 days) occurred in 18 (54.5%,
18/33) patients; 14 (42.4%, 14/33) developed at least 1
major complication, and 10 (30.3%, 10/33) at least 1
minor complication (Table 7). Most common major
complications were dural tear (n ¼ 4), respiratory failure
(n ¼ 3), and deep wound infection (n ¼ 2). Common
minor complications were pulmonary embolism (n ¼ 5),
pleural effusion (n ¼ 4), and urinary tract infection
(n ¼ 2). After en bloc resection with negative margins
9 out of 13 (69.2%) patients had at least 1 complication,
and after intralesional resection or en bloc resection with
positive margins 9 out of 20 (45.0%) patients had at least 1
complication (P ¼ .284).
Fourteen (42.4%, 14/33) patients were readmitted after
a median time of 13 months (range 1-197 months); 4
(12.1%, 4/33) patients had at least 3 readmissions
(Table 7). After en bloc resection with negative margins,
2 out of 13 (15.4%) patients had at least 1 readmission,
and after intralesional resection or en bloc resection with
positive margins 12 out of 20 (60.0%) patients had at least
1 readmission (P ¼ .015). Thirteen (39.4%, 13/33)
patients required a reoperation, with a median of 2 reo-
perations (range 1-8 reoperations) (Table 7). Most com-
mon reoperations were irrigation and debridement in 11
(33.3%, 11/33) cases for infection (2 cases within 90
days), resection of a recurrence in 10 cases (30.3%, 10/
33), and reinstrumentation in 4 cases (12.1%, 4/33). After
en bloc resection with negative margins 2 out of 13
(15.4%) patients had at least 1 reoperation, and after
intralesional resection or en bloc resection with positive
margins, 11 out of 20 (55.0%) patients had at least 1
reoperation (P ¼ .032).
Table 2.Oncologic Status of Patients With Primary Chondrosarcoma in the Mobile Spine Treated by En Bloc ResectionWith Negative Margins
or En Bloc Resection With Positive Margins/Intralesional Surgery.
All Patients, n ¼ 33
En Bloc Negative
Margins, n ¼ 13
Intralesional/ En Bloc
Positive Margins, n ¼ 20
Oncologic Status n (%) n (%) n (%) Pa
Tumor location
Cervical 6 (18.2) 1 (7.7) 5 (25.0) .606
Thoracic 24 (72.7) 11 (84.6) 13 (65.0)
Lumbar 3 (9.0) 1 (7.7) 2 (10.0)
Tumor grade
Grade I 8 (24.2) 5 (38.5) 3 (15.0) .311
Grade II-III 25 (75.8) 8 (61.5) 17 (85.0)
MSTS Enneking staging
Stage IA-IB 8 (24.2) 5 (38.5) 3 (15.0) .289
Stage IIA-IIB 22 (66.7) 7 (53.8) 15 (75.0)
Stage III 3 (9.1) 1 (7.7) 2 (10.0)
Vessel involvement of the tumorb 5 (16.1) 0 (0) 5 (25.0) .158
Extraosseous extension of the tumorb 28 (93.3) 12 (92.3) 16 (84.0) .775
Preoperative tumor embolizationb 4 (12.5) 0 (0) 4 (20.0) .271
Preoperative radiotherapy 18 (54.5) 8 (61.5) 10 (50.0) .722
Preoperative chemotherapy 3 (9.1) 1 (7.7) 2 (10.0) .999
Abbreviation: MSTS, Musculoskeletal Tumor Society.
a P values are based on differences between the patients treated by en bloc resection with negative margins versus intralesional resection or en bloc resection with
positive margins.
bData for vessel involvement was available in 31 patients (94%), extraosseous tumor extension in 30 patients (91%), preoperative tumor embolization in 32
patients (97%), and tumor resection margins in 31 patients (94%).
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Figure 1. Flowchart displaying the treatment course for all 33 included patients.
Table 3. Surgical Characteristics for Patients With Primary Chondrosarcoma in the Mobile Spine Treated by En Bloc Resection With Negative
Margins or En Bloc Resection With Positive Margins/Intralesional Surgery.
All Patients, n ¼ 33
En Bloc Negative
Margins, n ¼ 13
Intralesional/En Bloc
Positive Margins, n ¼ 20
Surgical Characteristics n (%) n (%) n (%) Pa
Indication for surgery at our institution
Primary resection 14 (42.4) 7 (53.8) 7 (35.0) .472
Recurrent resection 19 (57.6) 6 (46.2) 13 (65.0)
Year of surgery
1984-2001 15 (45.5) 3 (23.1) 12 (60.0) .072
2002-2014 18 (54.5) 10 (76.9) 8 (40.0)
Surgical approach
Anterior 4 (12.1) 0 (0) 4 (20.0) .173
Posterior 9 (27.3) 3 (23.1) 6 (30.0)
Combined 20 (60.6) 10 (76.9) 10 (50.0)
Two-stage procedure 15 (45.5) 7 (53.8) 8 (40.0) .493
Intraoperative radiotherapy 9 (27.3) 4 (30.8) 5 (25.0) .999
a P values are based on differences between the patients treated by en bloc resection with negative margins versus intralesional resection or en bloc resection with
positive margins.
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Oncological Outcomes (n ¼ 33)
All 12 local recurrences occurred in patients who underwent
intralesional resection or en bloc resection with positive mar-
gins (60%, 12/20), while none recurred in the 13 patients who
had en bloc resection with negative margins (P¼ .002) (Figure
2). Six (18.2%, 6/33) patients developed metastases to the lung
(n ¼ 4), distant bone (n ¼ 2), brain (n ¼ 1), soft tissue of the
neck (n ¼ 1), and periaortic region (n ¼ 1) (Figure 3). Eleven
(33.3%, 11/33) patients died of disease after a median of 7 years
(IQR 1.2-12 years) (Figure 4); 10 (50.0%, 10/20) died of
disease after intralesional resection or en bloc resection with
positive margins, and 1 died of disease after en bloc resection
with negative margins (P ¼ .064)
Neurologic Status (n ¼ 33)
Among 11 patients with preoperative neurologic deficits, 6
(66.7%, 6/9) improved, 2 (22.2%, 2/9) had neurologic decline,
and 1 (11.1%, 1/9) had no change. Neurologic status at follow-
up could not be established for 2 patients.
Discussion
We found that after a median follow-up of 5 years, patients who
underwent surgery for spinal chondrosarcoma reported worse
physical function and quality of life compared with the US
population average. Reoperation was associated with worse
physical function and quality of life. Complication rates, read-
mission rates, and reoperation rates were high. Readmission,
reoperation, and local recurrence rates were higher after intra-
lesional or en bloc resection with positive margins as compared
with en bloc resection with negative margins. No other studies
have reported on patient-reported outcomes after surgical
resection of spinal chondrosarcoma. Srivastava et al37 handed
out a disease-specific questionnaire (ie, the EORTC QLQ-C30)
to 17 spinal chordoma/chondrosarcoma patients before and at
the end of proton beam therapy; quality-of-life scores were
maintained in the majority of the patients during the course
of proton beam therapy. Van der Geest et al15 analyzed quality
of life 7 years after treatment for—non-spinal—chondrosar-
coma. Compared with healthy controls, patients with chondro-
sarcoma performed inferiorly in several quality-of-life domains
(fatigue, physical function, and sleep). Melcher et al38 report on
Table 4. Duration of Procedure and Blood Loss.
Variable
Median
(Interquartile Range)
One-stage procedure (n ¼ 18)
Duration of procedure, hours 9 (7-12)
Blood loss during procedure, L 1 (1-2)
Two-stage procedure (n ¼ 15)
First stage duration of procedure, hours 7 (5-9)
Second stage duration of procedure, hours 8 (6-8)
First stage blood loss during procedure, L 2 (1-2)
Second stage blood loss during procedure, L 2 (1-6)
Table 5. Patient-Reported Outcome Measures (n ¼ 14).
PROMIS–Physical
Function
PROMIS–Pain
Intensity EQ5D: Quality of Life Disability Indexa
Comparison Groups Median (IQR) Pb Median (IQR) Pb Median (IQR) Pb Median (IQR) Pb
US population average 50
.026
50
.362
0.85
.022
— —
Entire cohort (n ¼ 14) 43 (31-52) 47 (44-52) 0.70 (0.58-0.81) 25 (12-53)
Indication for surgery at our institution
Primary resection (n ¼ 5) 45 (45-52)
.162
44 (44-46)
.313
0.81 (0.73-0.92)
.327
14 (6-20)
.095
Resection of recurrence (n ¼ 9) 41 (29-43) 51 (46-52) 0.67 (0.36-0.69) 48 (18-54)
Resection þ margin
Intralesional/En bloc, positive margin (n ¼ 5) 31 (29-41)
.162
51 (46-52)
.687
0.59 (0.36-0.68)
.182
18 (12-30)
.182
En bloc, negative margins (n ¼ 9) 45 (42-52) 46 (44-52) 0.73 (0.69-0.81) 53 (48-54)
Pathologic tumor grade
Grade I (n ¼ 5) 43 (31-45)
.842
46 (44-49)
.737
0.67 (0.58-0.73)
.386
20 (18-48)
.894
Grade II-III (n ¼ 9) 42 (37-52) 51 (44-52) 0.72 (0.68-0.92) 30 (6-53)
Postoperative complications
None (n ¼ 5) 43 (41-45)
.842
46 (44-48)
.382
0.73 (0.68-0.80)
.593
20 (18-48)
.790
At least 1 complication (n ¼ 9) 42 (31-52) 51 (44-56) 0.69 (0.58-0.81) 30 (12-54)
Readmissions
None (n ¼ 9) 45 (42-52)
.205
46 (44-52)
.687
0.73 (0.69-0.81)
.182
18 (12-30)
.230
At least 1 readmission (n ¼ 5) 31 (29-41) 51 (46-52) 0.58 (0.36-0.69) 53 (48-54)
Reoperations
None (n ¼ 9) 45 (43-54)
.004
44 (43-48)
.051
0.80 (0.72-0.92)
.004
14 (6-20)
.003
At least 1 reoperation (n ¼ 5) 29 (23-31) 52 (51-56) 0.36 (0.04-0.58) 54 (53-58)
Abbreviations: EQ5D, EuroQol 5 Dimensions; IQR, interquartile range; PROMIS, Patient-Reported Outcomes Measurement Information System.
aThe Oswestry Disability Index in 12 patients and the Neck Disability Index in 2 patients.
b Boldfaced P value indicates significance (P < .05).
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15 patients after total en bloc spondylectomy of primary malig-
nant bone tumors or solitary metastases; quality of life was
decreased for all individual scales when compared with (Ger-
man) normal population values but exceeded values for chronic
back pain patients. In another study, health-related quality of
life (SF-36) was decreased for patients alive with disease, when
compared to those with no evidence of disease after en bloc
resection of primary malignant bone tumors or solitary metas-
tases.39 Mazel et al40 report on 25 patients with primary bone
tumors or single metastatic disease; quality of life was compa-
rable to general (French) population values, and lower for those
with a secondary tumor or those who had multiple levels
resected. Colman et al41 showed worse quality of life and
physical function than average (US) population values for
patients with mobile spine tumors (benign, malignant, and soli-
tary metastasis). Kato et al42 demonstrated that physical health
was impaired in the early postoperative years after en bloc
spondylectomy; this returned to normal approximately 3 years
Table 7. Complications (90 Days), Readmissions, and Reoperations After Resection for Patients With Chondrosarcoma of the Mobile Spine
(n ¼ 33).
All Patients,
n ¼ 33
En Bloc Negative
Margins, n ¼ 13
Intralesional/En Bloc
Positive Margins, n ¼ 20
Complications (90 Days)a n (%) n (%) n (%)
Major complicationsb
Dural tear 4 (12.1) 2 (15.4) 2 (10.0)
Respiratory failure needing intubation 3 (9.1) 2 (15.4) 1 (5.0)
Deep infection 2 (6.1) 1 (7.7) 1 (5.0)
Fistula (pleuro-incisional) 1 (3.0) 1 (7.7) 0
Cardiac arrest during surgery 1 (3.0) 1 (7.7) 0
Failure of instrumentation 1 (3.0) 0 1 (5.0)
Recurrence with spinal cord compression 1 (3.0) 0 1 (5.0)
Sternal osteomyelitis 1 (3.0) 0 1 (5.0)
Pneumothorax 1 (3.0) 1 (7.7) 0
Sepsis 1 (3.0) 1 (7.7) 0
Atrial thrombus 1 (3.0) 0 1 (5.0)
Minor complicationsc
Pulmonary embolism 5 (15.1) 2 (15.4) 3 (15.0)
Pleural effusion 4 (12.1) 3 (23.1) 1 (5.0)
Urinary tract infection 2 (6.1) 2 (15.4) 0
Delirium 1 (3.0) 1 (7.7) 0
Pneumonia 1 (3.0) 1 (7.7) 0
Superficial infection 1 (3.0) 0 1 (5.0)
Deep venous thrombosis 1 (3.0) 1 (7.7) 0
Readmissions n (%) n (%) n (%)
No readmission 19 (57.6) 11 (84.6) 8 (40.0)
1 readmission 4 (12.1) 1 (7.7) 3 (15.0)
2 readmissions 6 (18.2) 1 (7.7) 5 (25.0)
3 readmissions or more 4 (12.1) 0 4 (20.0)
Reoperationsd n (%) n (%) n (%)
Irrigation and debridement 11 (33.3) 3 (23.1) 8 (40.0)
Reresection 10 (30.3) 0 10 (50.0)
Reinstrumentation 4 (12.1) 0 4 (20.0)
Decompression 3 (9.1) 0 3 (15.0)
Decompression with reresection 2 (6.1) 0 2 (10.0)
Wound dehiscence 1 (3.0) 0 1 (5.0)
Dural tear repair 1 (3.0) 1 (7.7) 0
Epidural abscess removal 1 (3.0) 0 1 (5.0)
Paravertebral tissue excision 1 (3.0) 0 1 (5.0)
a Patients could have multiple complications within 90 days: 18 patients (55%) had at least 1 complication. 17 major complications and 15 minor complications
occurred.
bDefined as a Clavien Dindo grade III or IV complications (ie, complication requiring surgical, endoscopic or radiological intervention, or requiring management at
the intensive care unit).
cDefined as a Clavien Dindo grade II complications (ie, any deviation from the postoperative course requiring only pharmacological treatment).
d Thirteen patients (39%) required at least 1 reoperation with a median of 2 reoperations (range 1-8).
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after surgery, indicating that these surgeries require long recov-
ery periods. A comparison of quality of life (as measured by
EQ5D) among patients in our study (0.70) with other common
conditions shows that patients after resection of a chondrosar-
coma of the spine do worse than patients with diabetes (0.76),
asthma (0.82), and high blood pressure (0.79). However, their
quality of life is comparable to that of patients with angina
(0.71), myocardial infarction (0.73), and coronary artery dis-
ease (0.73) and slightly better than that of those who have
suffered a stroke (0.69). All dimensions measured by the EQ5D
among our patients were slight to moderately affected (ie,
physical function, pain, and mental health). We believe that
both the disease and the extensiveness of the surgery affects
quality of life. However, both aspects most likely affect differ-
ent dimensions of quality of life: For example, the disease
probably has more impact on mental health (worrying about
prognosis), whereas the surgery probably has more impact on
pain and physical function. The quality of life and physical
function among patients after resection of chondrosarcoma
of the spine in our study (median EQ5D 0.70, ODI 25) is
worse than a cohort of US patients from the Quality Out-
comes Database who underwent surgery for degenerative
spine conditions (including [recurrent-] disc herniation,
spondylolisthesis, stenosis, adjacent segment disease, and
disc collapse) at 12 months after surgery (median EQ5D
0.82, ODI 18, n ¼ 5443).44
Complication rates after spinal chondrosarcoma resection in
2 studies are 17% and 27%, although its definition and follow-
up is unclear.17,18 We focused on postoperative morbidity, and
found a higher overall complication rate (55%). Our reopera-
tion rate (42%) was comparable to a previous study (44%).18
Oncological outcome following surgical resection of mobile
spine chondrosarcoma is comparable to previous studies.
This study had limitations. First, we consider the short clin-
ical follow-up as the most important limitation; 30% had a
follow-up less than 1 year. A minimum follow-up period of
3 years is required before drawing conclusions on oncological
outcomes.4 Hence, our oncological outcomes should be inter-
preted with some caution. A previous study by our research
group reports oncologic outcomes after a minimum follow-up
of 2 years.5 Second, we had patient-reported outcomes for 70%
of eligible patients. The 19 patients for whom we did not have
patient-reported outcomes did not differ in age (P ¼ .228),
sex (P ¼ .427), type of resection (P ¼ .723), tumor grade
(P ¼ .316), complications (P ¼ .428), readmissions (P ¼ .723),
and reoperations (P ¼ .999). Therefore, we believe that our
results can be extrapolated to our complete cohort. Third, we set
the minimum follow-up for patient-reported outcomes at
6 months, although patients might need a longer recovery time
after these extensive surgeries. Patients whose questionnaires
were obtained between 6 to 12 months after surgery (21.4%,
3/14) did not have more complications (P ¼ .258), readmissions
(P ¼ .999), and reoperations (P ¼ .505). In addition, we did not
0
0.25
0.50
0.75
1.00
 
Pr
ob
ab
ili
ty
 o
f D
ist
an
t M
et
as
ta
sis
33 22 17 14 13 13 12 12 9 6 5Number at risk:
0 1 2 3 4 5 6 7 8 9 10
 Time in Years
Figure 3. Kaplan-Meier curve displaying the time to distant metastasis
for all 33 included patients. Hash marks on the curve represent cen-
soring of a patient (moment of lost to follow-up).
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Figure 4. Kaplan-Meier curve displaying disease specific survival for
all 33 included patients. Hash marks on the curve represent censoring
of a patient (moment of lost to follow-up, or death without presence
of disease).
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Figure 2. Kaplan-Meier curve displaying the time to local recurrence
for 33 included patients. Hash marks on the curve represent censoring
of a patient (moment of lost to follow-up).
Pereira et al 751
find a correlation between follow-up duration and any of the
patient0-reported outcome measures in our study (PROMIS–
Physical Function: r ¼ 0.21, P ¼ .49, PROMIS–Pain Interfer-
ence: r ¼0.36, P¼ .23, EQ5D Quality of Life: r¼ 0.35, P¼
.24, Disability Index: r¼ 0.21, P¼ .50; by Spearman correla-
tion); however, it should again be noted that the number of
patients with patient-reported outcome measures is limited.
Fourth, we did not collect preoperative patient-reported out-
comes; future studies should assess both preoperative and post-
operative patient-reported outcomes to assess changes due to
surgery and also assess the recovery of patient-reported outcome
measures over time (months to years) after surgery. Fifth—as in
other studies35—we combined the NDI and ODI into one score,
although there is literature supporting that there might be differ-
ences.36 Sixth, although radiation for chondrosarcoma is contro-
versial; there is some evidence that high-dose (photon and proton
combined) radiation has an effect.13 A recent study on spine
chordoma demonstrates that patients who underwent preopera-
tive radiation do better than postoperative radiation.We extrapo-
lated this and use preoperative high-dose radiation in
chondrosarcoma. Preoperative radiation also allows a more
focused field of radiation involving gross tumorwith only a small
margin.13 Seventh, this is a retrospective study including patients
over a long time span and with a limited sample size, which is a
result of the rarity of mobile spine chondrosarcoma (incidence of
chondrosarcoma in the United States is 1 in about 200000 per
year, of which 4-10% is in the mobile spine).43
Conclusion
Chondrosarcoma affects quality of life and physical function
and its treatment frequently results in complications and reo-
perations. Our findings can be used to inform future patients
about expected outcomes.
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